AGC
HZNP

Angelo Gordon & Co’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Angelo Gordon & Co’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-155,000
Closed -$17.9M – 91
2023
Q3 		$17.9M Sell
155,000
-20,000
-11% -$2.15M 6.91% 4
2023
Q2 		$18M Buy
175,000
+45,000
+35% +$4.75M 4.85% 4
2023
Q1 		$14.2M Buy
130,000
+110,000
+550% +$12.2M 3.55% 4
2022
Q4 		$2.28M Buy
+20,000
New +$1.66M 0.42% 34

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Angelo Gordon & Co's HZNP Position: Q4 2023 in Review

Angelo Gordon & Co sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 155,000 shares — an estimated $17.9M sold.

Angelo Gordon & Co first reported a position in HZNP in Q4 2022 and held it in 4 quarters. The position peaked at $18M in Q2 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Angelo Gordon & Co reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Angelo Gordon & Co sold 155,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $17.9M.
  • Angelo Gordon & Co first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 4 quarters.
  • Angelo Gordon & Co's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $18M in Q2 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Angelo Gordon & Co's 13F filing for Q4 2023, filed 14 Feb 2024.